CD8+ T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Tyler, Andrew F ^a   Mendoza, Jason P ^a   Firan, Mihail ^a   Karandikar, Nitin J ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLATIRAMER; INDOLEAMINE 2,3 DIOXYGENASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERFORIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; HLA ANTIGEN CLASS 1; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PEPTIDE FRAGMENT;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; IMMUNIZATION; IMMUNOTHERAPY; IN VIVO STUDY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT OUTCOME; ADOPTIVE TRANSFER; ANIMAL; C57BL MOUSE; CD4+ T LYMPHOCYTE; CYTOLOGY; CYTOTOXICITY; DEFICIENCY; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; REGULATORY T LYMPHOCYTE;

MURINAE;

ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GLATIRAMER ACETATE; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, REGULATORY;

EID: 84879274140     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066772     Document Type: Article

References (48)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG, (2000) Multiple sclerosis. N Engl J Med 343: 938-952.
2. Frohman EM, Racke MK, Raine CS, (2006) Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 354: 942-955.
3. Baxter AG, (2007) The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol 7: 904-912.
4. Miller SD, Karpus WJ, Davidson TS (2010) Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol Chapter 15: Unit 15 11.
5. Gold R, Linington C, Lassmann H, (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129: 1953-1971.
6. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M, (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1: 242-248.
7. Aharoni R, Teitelbaum D, Leitner O, Meshorer A, Sela M, et al. (2000) Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci U S A 97: 11472-11477.
8. Aharoni R, Teitelbaum D, Sela M, Arnon R, (1998) Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 91: 135-146.
9. Hong J, Li N, Zhang X, Zheng B, Zhang JZ, (2005) Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A 102: 6449-6454.
10. Kala M, Rhodes SN, Piao WH, Shi FD, Campagnolo DI, et al. (2010) B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol 221: 136-145.
11. Illes Z, Stern JN, Keskin DB, Reddy J, Brosnan CF, et al. (2005) Copolymer effects on microglia and T cells in the central nervous system of humanized mice. Eur J Immunol 35: 3683-3693.
12. Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, et al. (2009) Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A 106: 4355-4359.
13. Toker A, Slaney CY, Backstrom BT, Harper JL, (2011) Glatiramer acetate treatment directly targets CD11b(+)Ly6G(-) monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis. Scand J Immunol 74: 235-243.
14. Jung S, Siglienti I, Grauer O, Magnus T, Scarlato G, et al. (2004) Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate. J Neuroimmunol 148: 63-73.
15. Sellebjerg F, Hesse D, Limborg S, Lund H, Sondergaard H, et al. (2012) Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis. Mult Scler.
16. Ziemssen T, Schrempf W, (2007) Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol 79: 537-570.
17. Karandikar NJ, Crawford MP, Yan X, Ratts RB, Brenchley JM, et al. (2002) Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest 109: 641-649.
18. Biegler BW, Yan SX, Ortega SB, Tennakoon DK, Racke MK, et al. (2006) Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis. J Neuroimmunol 180: 159-171.
19. Tennakoon DK, Mehta RS, Ortega SB, Bhoj V, Racke MK, et al. (2006) Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 176: 7119-7129.
20. Tsai S, Shameli A, Yamanouchi J, Clemente-Casares X, Wang J, et al. (2010) Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 32: 568-580.
21. Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, et al. (2004) 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 10: 1088-1094.
22. Kim HJ, Verbinnen B, Tang X, Lu L, Cantor H, (2010) Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance. Nature 467: 328-332.
23. York NR, Mendoza JP, Ortega SB, Benagh A, Tyler AF, et al. (2010) Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis. J Autoimmun 35: 33-44.
24. Baughman EJ, Mendoza JP, Ortega SB, Ayers CL, Greenberg BM, et al. (2011) Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis. J Autoimmun 36: 115-124.
25. Theil DJ, Libbey JE, Rodriguez F, Whitton JL, Tsunoda I, et al. (2008) Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis. J Neuroimmunol 204: 92-100.
26. Najafian N, Chitnis T, Salama AD, Zhu B, Benou C, et al. (2003) Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest 112: 1037-1048.
27. Pamer E, Cresswell P, (1998) Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 16: 323-358.
28. Schoenborn JR, Wilson CB, (2007) Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96: 41-101.
29. Hurgin V, Novick D, Werman A, Dinarello CA, Rubinstein M, (2007) Antiviral and immunoregulatory activities of IFN-gamma depend on constitutively expressed IL-1alpha. Proc Natl Acad Sci U S A 104: 5044-5049.
30. Farina C, Then Bergh F, Albrecht H, Meinl E, Yassouridis A, et al. (2001) Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain 124: 705-719.
31. Jee Y, Liu R, Bai XF, Campagnolo DI, Shi FD, et al. (2006) Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? Int Immunol 18: 537-544.
32. Beeston T, Smith TR, Maricic I, Tang X, Kumar V, (2010) Involvement of IFN-gamma and perforin, but not Fas/FasL interactions in regulatory T cell-mediated suppression of experimental autoimmune encephalomyelitis. J Neuroimmunol 229: 91-97.
33. Li J, Goldstein I, Glickman-Nir E, Jiang H, Chess L, (2001) Induction of TCR Vbeta-specific CD8+ CTLs by TCR Vbeta-derived peptides bound to HLA-E. J Immunol 167: 3800-3808.
34. Lu L, Kim HJ, Werneck MB, Cantor H, (2008) Regulation of CD8+ regulatory T cells: Interruption of the NKG2A-Qa-1 interaction allows robust suppressive activity and resolution of autoimmune disease. Proc Natl Acad Sci U S A 105: 19420-19425.
35. Sarantopoulos S, Lu L, Cantor H, (2004) Qa-1 restriction of CD8+ suppressor T cells. J Clin Invest 114: 1218-1221.
36. Braud VM, Allan DS, McMichael AJ, (1999) Functions of nonclassical MHC and non-MHC-encoded class I molecules. Curr Opin Immunol 11: 100-108.
37. Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, et al. (2007) Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 13: 935-943.
38. Gajewski TF, Meng Y, Harlin H, (2006) Immune suppression in the tumor microenvironment. J Immunother 29: 233-240.
39. Mellor AL, Munn DH, (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4: 762-774.
40. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, et al. (1999) Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189: 1363-1372.
41. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, et al. (2000) Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164: 3596-3599.
42. Tonkin DR, Haskins K, (2009) Regulatory T cells enter the pancreas during suppression of type 1 diabetes and inhibit effector T cells and macrophages in a TGF-beta-dependent manner. Eur J Immunol 39: 1313-1322.
43. Gianfrani C, Levings MK, Sartirana C, Mazzarella G, Barba G, et al. (2006) Gliadin-specific type 1 regulatory T cells from the intestinal mucosa of treated celiac patients inhibit pathogenic T cells. J Immunol 177: 4178-4186.
44. Mitne S, Teixeira SH, Schwartz M, Belkin M, Farah ME, et al. (2011) The potential neuroprotective effects of weekly treatment with glatiramer acetate in diabetic patients after panretinal photocoagulation. Clin Ophthalmol 5: 991-997.
45. Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL, (1998) Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones. Proc Natl Acad Sci U S A 95: 12528-12531.
46. Aharoni R, Yussim A, Sela M, Arnon R, (2005) Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection. Int Immunopharmacol 5: 23-32.
47. Sand KL, Knudsen E, Rolin J, Al-Falahi Y, Maghazachi AA, (2009) Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. Cell Mol Life Sci 66: 1446-1456.
48. Van Rooijen N, Sanders A, (1994) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174: 83-93.